Current Report Filing (8-k)
July 13 2021 - 6:04AM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-07-12
2021-07-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
July 12, 2021
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (858) 997-2400
(Former name or Former Address, if Changed Since
Last Report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on
which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On July 12, 2021, Adamis Pharmaceuticals Corporation (the “Company”) posted an investor presentation to its website in connection with presentations that its executives plan to make and various investor meetings. The investor presentation is available under the “Events and Presentations” tab in the “Investors” section of the Company’s website, located at www.adamispharma.com. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.
The
information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language
in such filing, except as may be expressly set forth by specific reference in such filing or document. Item 7.01 of this Report and the
furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained
in the presentation is summary information that is intended to be considered in the context of more complete information included in the
Company’s filings with the U.S. Securities and Exchange Commission and other public announcements that the Company has made and
may make from time to time by press release or otherwise. Except to the extent required by applicable law, the Company undertakes no duty
or obligation to update or revise the information contained in this report or in the presentation.
Item 9.01 Financial
Statements and Exhibits
(d) Exhibits.
Exhibit No.
|
|
Exhibit Description
|
|
|
|
99.1
|
|
Investor Presentation dated July 2021
|
104
|
|
Cover page interactive data file (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: July 12, 2021
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024